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A B S T R A C T
The transcription factor Nrf2 (NF-E2-related factor 2) plays a vital role in maintaining cellular
homeostasis, especially upon the exposure of cells to chemical or oxidative stress, through its ability to
regulate the basal and inducible expression of a multitude of antioxidant proteins, detoxiﬁcation
enzymes and xenobiotic transporters. In addition, Nrf2 contributes to diverse cellular functions
including differentiation, proliferation, inﬂammation and lipid synthesis and there is an increasing
association of aberrant expression and/or function of Nrf2 with pathologies including cancer,
neurodegeneration and cardiovascular disease. The activity of Nrf2 is primarily regulated via its
interaction with Keap1 (Kelch-like ECH-associated protein 1), which directs the transcription factor for
proteasomal degradation. Although it is generally accepted that modiﬁcation (e.g. chemical adduction,
oxidation, nitrosylation or glutathionylation) of one or more critical cysteine residues in Keap1
represents a likely chemico-biological trigger for the activation of Nrf2, unequivocal evidence for such a
phenomenon remains elusive. An increasing body of literature has revealed alternative mechanisms of
Nrf2 regulation, including phosphorylation of Nrf2 by various protein kinases (PKC, PI3K/Akt, GSK-3b,
JNK), interaction with other protein partners (p21, caveolin-1) and epigenetic factors (micro-RNAs -144,
-28 and -200a, and promoter methylation). These and other processes are potentially important
determinants of Nrf2 activity, and therefore may contribute to the maintenance of cellular homeostasis.
Here, we dissect evidence supporting these Keap1-dependent and -independent mechanisms of Nrf2
regulation. Furthermore, we highlight key knowledge gaps in this important ﬁeld of biology, and suggest
how these may be addressed experimentally.
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The exposure of cells to a range of environmental toxicants,
mutagens and potential carcinogens has been linked to the
pathogenesis of a broad range of diseases including cancer,
neurodegenerative disease, cardiovascular disease and inﬂamma-
tion [1]. To protect against such insults, eukaryotic cells haveAbbreviations: DEA-NO/AM, acetoxymethylated diethylamine-NONO-ate; LC-ESI
MS/MS, liquid chromatography electronspray ionisation tandem mass spectrome-
try; MRM, multiple reaction monitoring; tBHQ, tert-butylhydroquinone; CDDO-Me,
methyl-2-cyano-3,12 dioxoolean-1,9 diene-28-oate; CDDO-Im, 1[2-cyano-3,12-
dioxooleana-1,9(11)-dien-28-oyl] imidazole.
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Open access under CC BY license.developed complex signalling cascades to detoxify potentially
harmful substances and maintain cellular redox homeostasis. One
of these signalling cascades is responsible for the induction of
cytoprotective and detoxifying enzymes consisting of phase I
(cytochrome P450s) and phase II (detoxifying and antioxidant
proteins) enzymes [2]. The co-ordinated expression of these genes
removes the insult and attempts to restore the cell to a basal state
by conferring a resistance to stress, thus preventing damage to
cellular components sensitive to redox changes (i.e. proteins, lipids
and DNA) [3]. The ubiquitously expressed cap’n’collar bZip
transcription factor Nrf2 is largely responsible for the basal and
inducible expression of proteins involved in drug metabolism, the
oxidative stress response and cytoprotection. Supplementary to its
primary role in cytoprotection, Nrf2 is also linked to differentia-
tion, proliferation, growth, apoptosis and it is thought that Nrf2 has
evolved from an original role in haematopoiesis and the regulation
of cell differentiation from early lineages [4]. Whilst a study by
Chan et al., showed that Nrf2 is not essential for growth,
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suggest that Nrf2 could still have originally played this role in an
avian system, due to observations made by Itoh et al. of high Nrf2
expression in chicken hematopoietic cells [5,6]. Furthermore, there
is still evidence of Nrf2s role in haematopoiesis in a mammalian
system as it regulates the expression of haemoxygenase-1 (HO-1)
which is involved in the handling of iron [7]. In addition, recent
ﬁndings show that Nrf2 is functionally involved in lipid deposition
in the liver. Using proteomic analysis (iTRAQ) to compare wild type
(WT) and Nrf2 knockout (Nrf2/) mice, it was shown that basally,
Nrf2 regulates a number of proteins involved in the synthesis and
metabolism of fatty acids and other lipids [8]. The most potent
known Nrf2 inducers; the triterpenoids CDDO-Me and CDDO-Im
(synthesised from oleanolic acid) are lipid soluble molecules which
have been shown to reduce the accumulation of lipids in the livers
of mice on a high fat diet via the Keap1/Nrf2 pathway [9]. The
importance of the basal control of lipid metabolism by Nrf2 is not
understood. However it is possible that this process is under the
control of Nrf2 when the cell is in a basal, energy-sufﬁcient state
yet, in times of stress and when Nrf2 is induced, lipid synthesis and
other biosynthetic pathways are down-regulated to compensate
for the energy requirements of cell defence mechanisms.
A vital factor in the functioning of many transcription factors is
their spatio-temporal regulation and this is no different in the case
of Nrf2; it is just as important that Nrf2 is switched on in response
to a stimulus as it is that it is switched off when the stimulus has
been removed. It is for this reason that this pathway is highly
regulated with a number of different mechanisms responsible forFig. 1. (A) Schematic overview of the Nrf2 pathway. Under basal conditions, Nrf2 is seque
proteasomal degradation of Nrf2. When the cell is faced with an insult such as chemic
cysteine residues results in the release of Nrf2 from one Keap1 molecule. Nrf2 can no lo
Nrf2, allowing newly synthesised Nrf2 to accumulate and translocate to the nucleus. Here
element (ARE). This activates the expression of a battery of genes responsible for removin
state. (B) Keap1 and Nrf2 Protein Domains. Keap1 contains a number of functional doma
linker domain (IVR), the double glycine/Kelch repeats and the C-terminal region. The BTB
contain the region responsible for binding Nrf2, facilitated in particular by a number of ar
residues also highlighted. Nrf2 contains Neh1-6 domains of which Neh1 binds to the A
binding to Keap1 via the 29DLG31 and 79ETGE82 motifs which ﬂank an a helix region cpreventing the aberrant activation of Nrf2. One of the most
important mechanisms that regulate the cells response to
inﬂammatory, hypoxic, oxidative and xenobiotic stimuli is
proteasomal degradation; and the Nrf2 pathway is no exception
to this. [10]. In unstressed conditions, the level of Nrf2 protein in
the cell is maintained at very low levels by its inhibitor Keap1,
which sequesters Nrf2 in the cytosol and facilitates its degradation
via the proteasome. Under conditions of stress or in the presence of
Nrf2 activating compounds, this degradation is hindered and Nrf2
translocates to the nucleus. Here, Nrf2 heterodimerises with small
masculoaponeurotic ﬁbrosarcoma (Maf) proteins which in turn
facilitate the binding of Nrf2 to the Antioxidant Response Element
(ARE), a cis-acting enhancer sequence (TCAG/CXXXGC) in the
promoter region of Nrf2-regulated genes [11,12] (Fig. 1a). These
Nrf2-regulated genes can be classiﬁed into phase II xenobiotic-
metabolizing enzymes antioxidants, molecular chaperones, DNA
repair enzymes, and anti-inﬂammatory response proteins [13] and
they reduce reactive compounds such as electrophiles and free
radicals to less toxic intermediates whilst increasing the ability of
the cell to repair any damage ensued. Importantly, Nrf2 has been
shown to possess an ARE sequence within its own promoter region
providing a platform for Nrf2 to initiate its own transcription
further enhancing the adaptive cell defence response [11].
Following its nuclear import, Nrf2 recruits transcriptional ma-
chinery to effectively transactivate the ARE-driven genes. This
machinery includes co-activators such as receptor associated co-
activator (RAC3) which initiates the transactivation domain of Nrf2
whilst the presence of other co-regulators such as CREB bindingstered in the cytosol by a Keap1 homodimer which facilitates the ubiquitination and
al or oxidative stress, a conformational change in Keap1 mediated via its reactive
nger be ubiquitinated and degraded therefore Keap1 becomes fully saturated with
 Nrf2 heterodimerises with small Maf proteins and binds to the antioxidant response
g the insult, conferring increased resistance to stress and returning the cell to a basal
ins including the Broad complex, Tramtrack and Bric-a-brac (BTB), the intervening
 is responsible for the dimerisation of two Keap1 molecules whilst the Kelch repeats
ginine residues (Arg-380, -415, -483). Keap1 contains a number of reactive cysteine
RE within DNA whilst Neh4/5 are transactivation domains. Neh2 is responsible for
ontaining the lysine residues for Keap1-mediated ubiquitination.
Table 1
The major classes of Nrf2 inducers and their structures. Where more than one example is given, the structure shown is that of the example in bold type.
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(CARM1) and protein arginine methyl-transferase (PRMT1),
further enhance the ability of RAC3 to initiate the transactivation
domain [14].
The discovery of the ARE lead to the identiﬁcation of Nrf2 as the
transcription factor capable of both binding to this DNA sequence
and inducing the expression of cell defence genes and resulted in a
burst of research into this pathway as a potential therapeutic
target. The vast number of both natural and synthetic compounds
able to induce Nrf2 can be divided into at least 10 groups outlined
in Table 1. The pharmacological activation of Nrf2 by various
compounds such as allyl sulﬁdes, dithiolethiones, ﬂavonoids,
isothiocynates, polyphenols and triterpenoids has been proposed
for use in the prevention of a number of diseases associated with
oxidative stress [4]. A number of Nrf2 inducers, mostly plant-
derived compounds with chemopreventive properties, such as
sulforaphane (broccoli) [15], curcumin (turmeric) [16,17] andresveratrol (grapes) [18,19] are currently in clinical trials for a
variety of cancers. Interestingly there is some dispute over the
exact role of Nrf2 in cancer as it seems to play a dual role
potentially acting as both a tumour suppressor and an oncogenic
factor. Recent observations include mutations in the Nrf2 or Keap1
genes which result in aberrant expression or ineffective regulation
of Nrf2. Raised Nrf2 levels have been detected across an array of
cancer tissues including lung [20,21] and pancreas [22,23] and it is
proposed that this provides cells with enhanced chemo-resistance
as well as supporting increased proliferation thus promoting
cancer growth and development [22]. Nrf2-deﬁcient mice are more
susceptible to toxicity by a number of compounds such as
paracetamol and tobacco smoke and to many diseases (neurode-
generative, cancer, inﬂammation) but interestingly, Nrf2/ mice
do survive and are able to procreate which suggests that, although
some constitutively active processes are under Nrf2 control (e.g.
lipid homeostasis), Nrf2 is not necessarily vital for survival in
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insult. [24]. What is evident, however, is that Nrf2 plays a major
role in health and disease and it is not surprising that Nrf2 is
considered to be a potential therapeutic target. For a detailed
review of the potential of Nrf2 as a therapeutic target, see the
review by Copple [25]. The development of a number of Nrf2
inducers as possible pharmacological agents without a complete
knowledge of the workings of this pathway and its regulation
heightens the need to further our understanding and to determine
whether activation of Nrf2 would be beneﬁcial in both the short-
and long-term.
The protein primarily responsible for the regulation of Nrf2 is
Kelch-like ECH-associated protein 1 (Keap1), which forms a
homodimer responsible for sequestering Nrf2 in the cytosol,
thereby rendering it inactive. It is an association between Keap1
and the actin cytoskeleton which prevents this complex entering
the nucleus, limiting basal activity of the transcription factor
[26].Additionally, Keap1 facilitates the Cul3-mediated poly-ubi-
quitination of Nrf2 leading to its proteasomal degradation. Whilst
Keap1 seems to be the major mechanism by which Nrf2 levels are
tightly controlled in the cell, recent research would suggest that
the pathway is highly complex and supports a multi-faceted
defence system. In this commentary we focus on the mechanisms
by which Keap1 regulates the Nrf2 pathway under basal and
stressed conditions and also how it is that Keap1 has become
known as a redox-sensor with the role of sensing environmental
conditions and facilitating the up-regulation of the cell defence
pathway via Nrf2. Furthermore we explore a number of mecha-
nisms by which Nrf2 can be regulated independently of Keap1 at
the level of protein transcription, translation and by post
translational modiﬁcations.
2. Keap1 dependent regulation
2.1. Identiﬁcation of Keap1 as an inhibitor of Nrf2
The identiﬁcation of an inhibitor of Nrf2 arose from observa-
tions by Itoh et al. that the deletion of the Neh2 region of the Nrf2
protein resulted in a marked increase in Nrf2 activity in
erythroblasts and led to the proposal that this region was
responsible for the negative regulation of Nrf2 via an interaction
with a repressor protein [27]. Itoh et al. then used yeast-two-
hybrid – with the Neh2 domain of Nrf2 as the bait – to identify a
mouse protein homologous to the Drosophila protein Kelch and
termed the protein Keap1. Later observations by Dhakshina-
moorthy et al. further conﬁrmed this idea by cloning the rat
homologue of Keap1 by purifying Nrf2-interacting proteins [28].
Following these discoveries, the domains of Keap1 were char-
acterised and it was noted that two Keap1 molecules are able to
bind to one Nrf2 molecule [10] and that the BTB domain is
responsible for the homodimerisation of Keap1 and the subse-
quent inhibition of Nrf2 [29] (see Fig. 1b for domain structures of
Nrf2 and Keap1). When transfected into cells it was observed that
Nrf2 would accumulate in the nucleus, however when co-
transfected with Keap1 the two would co-localise in the cytoplasm.
Moreover, in the presence of both Keap1 and a panel of
electrophiles (e.g. diethylmaleate (DEM)), this co-localisation is
lost and Nrf2 again localises in the nucleus [30]. This promoted the
idea that Keap1 sequesters Nrf2 in an inactive form in the
cytoplasm until faced with an oxidative or electrophilic insult
when Nrf2 is freed and translocates to the nucleus. The importance
of Keap1 is highlighted by the observation that Keap1-deﬁcient
mice (Keap1/) do not survive longer than 3 weeks postnatally
due to hyperkeratosis of the digestive system resulting in
ulceration of the stomach [31]. Embryonic ﬁbroblasts isolated
from Keap1/mice showed constitutive activation of Nrf2 and theinducibility of Nrf2 regulated cell defence genes was hugely
reduced [31], demonstrating that Keap1 is vital in the regulation of
the Nrf2 pathway in vivo.
Having initially established that Keap1 plays an role in the
regulation of the Nrf2 pathway, is was questioned whether under
basal conditions, Keap1 is simply binding Nrf2 and sequestering it
in the cytosol thus preventing its translocation to the nucleus or
whether Keap1 also provided a functional role in this pathway. It
was quickly determined that the latter was the more likely.
2.2. Ubiquitination and proteasomal degradation of Nrf2
Under basal conditions, low levels of Nrf2 are maintained to
prevent the constitutive activation of the oxidative stress response.
It is the interaction with Keap1 that facilitates the proteasomal
degradation and high turnover of Nrf2 protein resulting in a half
life of approximately 10–20 min [32,33]. In the absence of
oxidative stress, Nrf2 is sequestered in the cytosol by the Keap1
homodimer which acts as a substrate adaptor for the ubiquitina-
tion of Nrf2 in a cullin-3 (Cul3) dependent manner [34]. Nrf2 binds
the DGR site of each Keap1 subunit via 2 distinct binding motifs in
its Neh2 domain, one high afﬁnity, 79ETGE82, and one low afﬁnity,
29DLG31 [10] (Fig. 1). The hinge and latch hypothesis proposes that
the high afﬁnity binding site (hinge) allows Nrf2 to bind Keap1
whilst still able to move freely, whilst the low afﬁnity binding site
acts as the latch that impedes the movement of Nrf2 and positions
the lysine residues within the Neh2 region for ubiquitination [10].
When bound at both sites, Nrf2 is perfectly positioned to undergo
poly-ubiquitination via the Cul3 E3 ligase and is consequently
degraded by the 26S proteasome ensuring extremely low basal
levels of Nrf2 in the cell (Fig. 1a).
When the cell experiences conditions of (oxidative) stress or in
the presence of electrophiles, it is proposed that subsets of the
cysteine residues in Keap1 are modiﬁed. These modiﬁcations
potentially result in a conformational change in the protein which
results in the release of Nrf2 from the low afﬁnity binding site
(latch), disturbing the transfer of ubiquitin. Keap1 molecules
become saturated with Nrf2 that is no longer targeted for
degradation and newly synthesised, free Nrf2 accumulates in
the cytosol. Consequently, Nrf2 translocates to the nucleus where
it binds to the ARE, activating the transcription of a host of cell
defence genes (Fig. 1b). The importance of Keap1 in this process is
clear, as the half life of Nrf2 increased from approximately 7.5–
15 min. in unstressed COS1 cells co-expressing mNrf2-V5 and
mKeap1 to 30 min in cells under the same conditions co-
expressing the mutant mNrf2
DETGE-V5 with wild-type mKeap1
[35]. The changes in Nrf2 half-life associated with oxidative stress
and speciﬁc electrophiles varies immensely between cell lines due
to the dramatic differences in detectable basal levels of the protein
[36–38]. There is also conﬂicting evidence on the mechanism by
which Nrf2 becomes free in the cell, some stating that electrophiles
cause the dissociation of the Keap1–Nrf2 complex [39,40] whilst
others suggest that the electrophiles cause the dissociation of Cul3
from Keap1 thus preventing the proteasomal degradation of Nrf2
[41–43]. There is also the possibility that whilst the ubiquitination
of Nrf2 ceases, ubiquitination of Keap1 increases under conditions
of chemical/oxidative stress however this is only seen with certain
Nrf2 inducers [44]. Furthermore, there are those who believe that
Nrf2 is primarily a nuclear protein and this nuclear localisation is
responsible for the basal expression of cell defence genes and that
the degradation of Nrf2 via Keap1 is downstream of Nrf2
transcriptional activity [45,46]. Whilst this would explain how
Nrf2 is capable of regulating the basal expression of genes despite
being constantly degraded via Keap1, this idea requires the
nucleo-cytoplasmic shuttling of Keap1 which others claim not to
observe [47]. What is certainly clear is that Keap1 is responsible for
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somehow dependent on the redox state of the cell and that this is at
least partially via the interaction with the redox-sensitive Keap1.
2.3. Autophagic degradation of Keap1
The proteasome has long been considered the machinery
utilised to carry out the degradation of speciﬁc proteins targeted
for destruction for reasons such as misfolding. On the other hand,
autophagy was generally regarded to be a bulk-degradation
pathway for the recycling of a multitude of non-speciﬁc cellular
organelles and proteins. However, there is growing evidence
supporting the notion that the latter pathway is capable of
degrading speciﬁc, targeted proteins [48–51].
The substrate adaptor Sequestosome1 (p62) acts as a scaffold
protein in various signalling pathways via its multiple protein–
protein interactions and binds to both poly-ubiquitinated proteins
as well as the autophagic machinery, speciﬁcally LC3, targeting
speciﬁc proteins for degradation via the autophagic pathway
[52,53]. Until recently Nrf2 was thought to be one of very few
substrates for Keap1 however a physical and functional relation-
ship between Keap1 and p62 has been elucidated [54–58].
Evidence suggests that p62 has a role in regulating Keap1
degradation via autophagy, altering the ability of the cell to
respond to various stresses via this pathway [58]. The ectopic
expression of p62 in a panel of cell lines resulted in reduced levels
of Keap1 protein whilst siRNA-mediated knockdown of p62
resulted in increased levels of Keap1 protein, decreased Nrf2
protein (without changes in mRNA) concurrent with reducedFig. 2. Schematic overview of human and mouse Keap1 cysteine residues and their modiﬁ
(black box) and mouse Keap1 cysteine residues (white box). The boxes outline the three c
outlined at the bottom of the ﬁgure and the cysteine numbers are annotated at the top and
biotinamido-4-4(40-[maleimidiethylcyclohexane]-carboxamido)butane [121,122]; IAB, N
MES, dexamethasone-21-mesylate [125]; ISO, isoliquiritigenin; SHO, 10-Shogaol; X
s-glutathionlyation [66]; NAPQI, N-acetyl-p-benzoquinoneimine; IA, iodoacetamide; D
prostaglandin J2 [67,74]; PGA2, prostaglandin A2; DEM, diethylmaleate [67] (adapted mRNA and protein levels of a number of Nrf2-regulated genes [58].
This change was associated with a 2-fold increase in the half-life of
Keap1 in the absence of p62 [58]. Further observations involving
this complex indicate a role for this interaction in hepatocellular
carcinoma whereby liver-speciﬁc autophagy deﬁcient mice
(Atg/) show p62 accumulation and the formation of p62/Keap1
aggregates alongside the development of the aforementioned
carcinoma; moreover, this p62 accumulation leads to the
consistent activation of Nrf2 which promotes the development
of human hepatocellular carcinoma [59]. The proposed model is
that under conditions of stress, a conformational change in Keap1
releases Nrf2 from the low afﬁnity binding site and p62 takes
advantage of this empty site and binds to Keap1 via an STGE motif,
a sequence similar to Nrf2s ETGE motif [54] and also to LC3 which
is associated with the autophagosome membrane, therefore
providing a link between the Keap1–Nrf2 complex and autophagic
degradation adding another level to the complexity of the
regulation of this pathway.
2.4. Keap1 as a sensor of stress
Having uncovered some of the mechanisms by which the Nrf2
pathway is regulated via the degradation of various components
under both basal and stressed conditions, the next question to be
answered is how the system senses the wide variety of stresses
that result in the de-repression of Nrf2.
The Keap1 protein is relatively cysteine rich with 4.3% of all
residues being cysteines; approximately double the number in the
average protein [60]. Cysteine residues are usually found withincation by electrophiles. Electrophile modiﬁcation of human Keap1 cysteine residues
ritical reactive cysteines of Keap1 (C151, C273 and C288). The domains of Keap1 are
 bottom of the ﬁgure. The abbreviations of the electrophiles are as follows: BMCC, 1-
-iodoacetyl-N-biotinylhexylenediamine [121,123]; SULF, sulforaphane [124]; DEX-
AN, xanthohumol [122]; LIQ, liqustilide [126]; P-SS-P, protein disulﬁde; P-SG,
NCB, dinitrochlorobenzene [74]; DEX-MES [65,74]; 15d-PGJ2, 15-deoxy-D12,14-
from Holland et al. [62]).
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responsive to the local environment [61]. It is Keap1’s 27 cysteine
residues that are proposed to be the main mechanism whereby
Keap1 is able to sense electrophilic or oxidative stresses [62]. The
majority of Keap1 cysteine residues are ﬂanked by basic amino
acids which increase the reactivity of the cysteine residue by
lowering the predicted pKa value [63]. Moreover, the majority of
Nrf2 inducers are electrophilic and capable of reacting with
cysteine sulfydryl groups and forming direct covalent adducts with
them. It is postulated that these residue modiﬁcations disrupt the
Keap1–Nrf2 association allowing Nrf2 to translocate to the nucleus
[64]. The hypothesis that the modiﬁcation of cysteines in Keap1
may be essential to the regulation of the Nrf2 pathway was ﬁrst put
forward by Dinkova-Kostova et al., who determined that a number
of Nrf2 inducers, whilst being structurally dissimilar, were all
reactive with thiol groups at rates that correlated with their
potency [65]. They showed that electrophiles are capable of
dissociating Keap1 from the Neh2 region of Nrf2, from which they
deduced that the sensor of the inducers must be Keap1, as the Neh2
region contains no cysteine residues. Using mass spectrometry
analysis, the group went on to show that a number of cysteine
residues that lie in the linker region between the BTB domain and
Kelch-repeats of the Keap1 protein; C257, C273, C288 and C297 are
especially reactive [65]. The idea that Keap1 may be under the
control of oxidation/reduction and alkylation opened up a number
of opportunities for the exploration of the importance of the role
these residues play in the regulation of the Nrf2 pathway.
This led to a vast quantity of literature regarding which cysteine
residue(s) are required for an Nrf2 response and a general
consensus on a selection of cysteines reactive to particular
electrophiles developed. Published data demonstrates that there
is not a single cysteine or selection of cysteines that are reactive to
all electrophiles [66] rather that there are some residues which are
more reactive than others (see Fig. 2 for an overview). As seen in
Fig. 2, it is clear that there are reactive cysteines across the whole
Keap1 sequence. However the residues that are reactive to most
electrophiles are those in the intervening linker region (IVR) of
Keap1 thus is it possible that modiﬁcation of any one/combination
of these cysteines is sufﬁcient to disrupt the association with Nrf2.
The modiﬁcation of a subset of cysteine residues in Keap1 by Nrf2
inducers with similar structures supports the hypothesis of a
‘‘cysteine code’’ and may underlie the ability of Nrf2 to respond to
such a diverse array of compounds [67]. Point mutation of Cys151
results in reduced activation of Nrf2 in response to some inducers
(tBHQ, DEM, sulforaphane) but not to others (CDDO-Im, mitro-
oleic acid, cadmium chloride) compared to wild type cells [68]. It is
proposed that Cys151 is important in the de-repression of Nrf2
whilst Cys273 and Cys288 are more important in the basal
repression of Nrf2. Transgenic expression of mutant Keap1
(Keap1C273A/Keap1C288A) into Keap1/ mice prevents the ability
of Keap1 to inhibit the constitutive activation of Nrf2, whilst
mutant CysC151S retained the ability to suppress Nrf2 but had
decreased expression levels of Nrf2-regulated genes both before
and after electrophilic insult [69]. McMahon et al. propose that
Keap1 quantiﬁes stress by monitoring endogenous levels of
messengers (NO, Zn+ and alkenals) which imply the presence of
stress within the cell, using at least 3 unique cysteine-based
sensors to confer the appropriate Nrf2 response [70]. They go on to
propose that whilst the NO-donor DEA-NO/AM does not form
direct adducts with Cys151, this cysteine may undergo S-
nitrosylation facilitated by its ﬂanking residues (K131, R135,
K150) [70] and this idea of S-nitrosylation of Keap1 is supported by
others [71,72]. Supplementary to these modiﬁcations, cysteine
residues can also be glutathionylated by oxidised glutathione
(GSSG) and this molecule can also cause the formation of disulﬁde
bridges [66]. This is important as under conditions of oxidativestress, the balance between oxidised and reduced glutathione
(GSSG:GSH) is altered, and it is possible that increased GSSG or
depleted GSH can enhance the activation of Nrf2, as can be seen, for
example after exposure of cells to buthionine sulfoximine (BSO), an
inhibitor of the rate-limiting enzyme in the glutathione synthetic
pathway [73,74]. These studies support the idea of a ‘‘multiple
sensor mechanism’’ within Keap1 and imply that it is most likely
the modiﬁcation of a combination of cysteines that is responsible
for the activation of Nrf2 as opposed to direct adduct formation
with one individual residue. Further studies exploiting recent
advances in techniques of mass spectrometry may allow better
understanding of this mechanism.
Due to the low abundance of Keap1 in most cell lines, the
approach of ectopically expressing various mutant forms of Keap1
has primarily been used to identify a battery of cysteines thought
to be most important in this pathway, namely Cys151, Cys273 and
Cys288. However, one must bear in mind when considering this
data that whilst the mutation of one or a number of cysteine
residues in Keap1 may prevent the up-regulation of an Nrf2
response, this does not necessarily mean that this cysteine residue
is primarily responsible for eliciting the Nrf2 response. One major
problem with this type of approach is that often it is not
determined whether the mutation made within the Keap1 protein
sequence causes any changes in the protein folding or structure
that may result in a non-functional Keap1 protein and an up-
regulation of Nrf2 independent of cysteine modiﬁcation. Further-
more, the practice of ectopically expressing a protein in a cell line
may divert the environment of the protein away from that of a
truly physiological state, the importance of which is yet to be
established. What one must also take into account is that adduct
formation may not be primarily responsible for the activation of
Nrf2 via Keap1. A number of adduct-forming electrophiles also
induce the formation of reactive oxygen species which are capable
themselves of activating Nrf2. Thus it is not yet plausible to claim
that the modiﬁcation of Keap1 is directly responsible for the
induction of Nrf2. Ultimately, it is clear that further exploration of
the importance of Keap1 cysteine modiﬁcation will help increase
our overall understanding of how activation and regulation of the
Nrf2 pathway occurs, and therefore how we sense and respond to
our chemical environment.
3. Keap1-independent regulation
Despite the aforementioned support for the regulation of Nrf2
via Keap1, a body of evidence is emerging showing that Nrf2 can be
regulated independently of Keap1. A study by Li et al. showed that
the Nrf2 inducer sulforaphane prevents the dissociation of Nrf2
from Keap1, supporting the view that there are alternative
mechanisms of Nrf2 activation that do not rely on Keap1 [4].
The expression level and function of a protein can be controlled by
regulation at various levels including; transcriptional, post-
transcriptional, protein abundance, post-translational modiﬁca-
tion and subcellular localisation. The phosphorylation of Nrf2 by
several signal transduction pathways, the involvement of epige-
netic factors such as microRNAs or the interaction of Nrf2 with
other proteins may also play a role in Nrf2 activation and this
section will describe these in detail.
3.1. Transcription regulation and autoregulation
The core DNA sequences, ARE and XRE (xenobiotic-responsive
element), are found in the promoter region of many cell defence
genes known to be regulated by Nrf2. Nrf2 binds to the ARE to up-
regulate gene expression whilst the XRE is activated by the
transcription factor AHR (aryl hydrocarbon receptor). Ligands
which activate AHR cause its heterodimerisation with ARNT (AHR
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the expression of many phase I enzymes such as cytochrome p450s
[75] which promotes the generation of reactive intermediates from
a parent compound and this reactive intermediate can potentially
activate the antioxidant pathway via the ARE. A study by Miao et al.
showed that TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin), a potent
inducer of AHR, also induces ROS as well as Nrf2 itself and can
therefore activate both the ARE and XRE pathways directly [2]. The
XRE and ARE elements are found in close proximity within the
promoters of several Nrf2 regulated genes (e.g. GST) as well as Nrf2
itself [2,76] (Fig. 3). The Nrf2 promoter region contains one XRE-
like element at position 712 and the Nrf2 mRNA initiation site
contains two XRE-like elements at position +755 and +850 [2].
The presence of these DNA binding sites (ARE/XRE) within the
promoter region of Nrf2 suggests the ability of Nrf2 to regulate its
own transcription – i.e. autoregulation. In support of this, Kwak
et al. showed that the potent ARE activator D3T (3H-1,2-dithiole-3-
thione) increased Nrf2 protein and mRNA levels and that these
increases were inhibited by co-treatment with the protein
synthesis inhibitor cyclohexamide [38]. Furthermore, they dem-
onstrated direct binding of Nrf2 to its own promoter region and
that the over-expression of Nrf2 increased the activity of a
luciferase reporter assay of the isolated proximal region of the Nrf2
promotor, whereas using mutant Nrf2 repressed the activity of the
luciferase reporter [38]. This evidence suggesting that Nrf2
activates its own expression hints at a positive feedback loop
within this pathway, leading to enhanced cell defence.
Since Nrf2 has been implicated in the pathogenesis of various
diseases and it is known that polymorphisms have been also beenFig. 3. Schematic overview of Keap1-independent regulation of Nrf2. Nrf2 has been show
regulation at the transcriptional level (1) by AHr-ARNT inducing Nrf2 expression and N
(dotted circle highlights that this is a suggestion and has not been proven experimentally)
by several micro-RNAs (miR-28, 34, 144, 200). Post translationally (3), Nrf2 is phosphory
translational modiﬁcation affects Nrf2 differently by altering; Nrf2’s interaction with Ke
protein degradation (GSK3b/bTrCP) and Nrf2 DNA binding (300/CBP, Maf). A number of p
their mechanisms of action are unknown.associated with susceptibility to pathologies which could be
associated with Nrf2 such as idiosyncratic drug reactions, it is
plausible that the Nrf2 gene contains polymorphisms that may
predispose individuals to certain health problems. A study by
Yamamoto et al. identiﬁed the presence of three single nucleotide
and one triplet repeat polymorphism in the regulatory region of
the Nrf2 gene [77]. In this study, no link was established between
the frequency of the polymorphism and the pathogenesis of
diseases such as lupus (SLE) or COPD. Furthermore, the coding
region of the gene showed no polymorphisms although a larger
population screening may be warranted. In contrast, Marzec et al.
identiﬁed multiple SNPs in the Nrf2 gene and saw a correlation
between the 617 SNP and the susceptibility to acute lung injury
(ALI) implicating Nrf2 in the development of this disease [78].
Since then, Nrf2 polymorphisms have been linked to diseases
including vitiligo and nephritis with polymorphism seen at 650C/
A and 635/A respectively [79]. What remains to be determined is
what effects these polymorphisms have on the expression levels
and activity of Nrf2 and whether this information can be used to
tailor drug regimes to individuals and increase drug safety.
NF-kB (nuclear factor k-light-chain-enhancer of activated B
cells) is a transcriptional factor involved in cellular processes such
as apoptosis, inﬂammation and development. NF-kB is associated
with its inhibitor IkB in the cytoplasm and is activated upon the
phosphorylation of IkB by IkB kinases (IKK), leading to the
dissociation of the complex and nuclear translocation. Many
chemopreventive agents are known to activate Nrf2 whilst
repressing NF-kB activity, moreover NF-kB can suppress the
transcription of ARE-dependent genes [80]. Cross-talk betweenn to be regulated by a number of mechanisms independent of Keap1. These include
F-kB which has been proposed to bind to an ARE with in the Nrf2 promotor region
. At the post-transcriptional level (2), components of the Nrf2 pathway are regulated
lated (P), ubiquitinated (Ub) and acetylated (Ac) by a variety of enzymes. Each post-
ap1 (ERK/JNK, PCK, MAPK/ERK, p38); Nrf2 localisation (PKC, CK2, GSK3b/Fyn); Nrf2
roteins have been identiﬁed as Nrf2 binding partners (4) (p21, caveolin-1) however
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in the promoter region of Nrf2 suggests that Nrf2 could be
regulated by NF-kB (Fig. 3) [80]. Interestingly, Keap1 has been
shown to bind to IKKb, a member of the IKK complex, promoting
its ubiquitination and degradation such that Keap1 plays a role in
the negative regulation of the NF-kB pathway [81,82]. The
regulation and interaction of these two transcription factors
requires further study to really establish where the crossover may
lie.
3.2. Post-transcriptional regulation: microRNAs
MicroRNAs (miRs) are short, single-stranded non-coding RNAs
of approximately 21–23 nucleotides in length. They are tran-
scribed from genetic loci by RNA polymerase II and processed
before being exported from the nucleus as short hairpin loops for
maturation and cleavage [83]. Upon maturation, these microRNAs
form a complex called the RNA-induced silencing complex (RISC)
which binds to target mRNAs at the 30UTR region and exerts its
function through mRNA degradation or protein translation
inhibition to inhibit protein expression [83]. MicroRNAs have
been the centre of a vast amount of research in the past few years
due to their ability to ﬁne-tune the regulation of various proteins
and processes, including the Nrf2 pathway. Micro-RNAs that have
been shown to be involved in the regulation of Nrf2 include miR-
144 [84], miR-28 [83], miR-200 [85] and miR-34 [86] (Fig. 3). The
Songkoya et al. study showed an inverse association between miR-
144 and Nrf2; an increase in miR-144 expression reduces Nrf2
protein levels, decreases glutathione regeneration and alters the
antioxidant capacity of erythroid cells, an important mobile
detoxiﬁcation system in the body [84]. Interestingly, an abnormal
expression of miR-144 has been associated with the sickle cell
disease (SCD) and this implicates a role for Nrf2 in this disease [84].
A similar relationship was seen between Nrf2 and miR-28 in
breast epithelial cells [83]. MiR-28 was shown to regulate Nrf2 by
binding facilitating the degradation of Nrf2 mRNA as well as
promoting the degradation of Nrf2 protein [83]. MiR-28 had no
effect on either Keap1 protein expression or the Keap1/Nrf2
interaction highlighting a mechanism by which Nrf2 is regulated
independently of Keap1 [83]. The aberrant expression of miR-28
has been seen in various cancers including lymphoma, glioma and
squamous carcinoma supporting previous evidence for a role of
Nrf2 in cancer. Other microRNAs shown to regulate Nrf2 include
miR-200 which targets Keap1 mRNA [85] and miR-34 which not
only targets Nrf2 but also downstream genes involved in the
oxidative stress response (Mgst1) suggesting a double-dampening
effect [86]. The actual mechanism by which micro-RNAs regulate
Nrf2 and other proteins requires further elucidation but current
hypotheses are reviewed by Filipowicz et al. [87].
3.3. Post-translational modiﬁcation: phosphorylation/acetylation
There have been several studies suggesting that phosphoryla-
tion of Nrf2 may contribute to its nuclear exclusion and
degradation. Nrf2 contains many serine, threonine and tyrosine
residues, which may provide sites for phosphorylation by different
kinases [88] and a number of different pathways have been
explored including mitogen-activated protein kinase cascades
(MAPK), the phosphatidylinositol 3-kinase (PI3K/AKT) pathway,
protein kinase C (PKC), GSK3b pathway and the ERK signalling
pathways (Fig. 3).
Protein kinase C has been shown to phosphorylate Nrf2 in its
Neh2 domain at Ser-40, disrupting the association between Nrf2
and Keap1 thus promoting the translocation of Nrf2 into the
nucleus [89]. Reduced nuclear translocation of Nrf2 was seen in
mutant Nrf2S40A compared to wild type Nrf2. PKC are a family ofserine/threonine kinases which can be subdivided into 3 classes;
classical, novel and atypical [90]. The isoforms require different co-
factors for activation and play different roles in growth,
differentiation, apoptosis, survival and carcinogenesis. They can
be activated upon oxidative stress, a principal activator of the Nrf2
antioxidant pathway and a study by Numazawa et al. showed that
the atypical isoform is responsible for the phosphorylation and
nuclear translocation of Nrf2 to induce phase II cytoprotective
proteins [90]. In contrast to this, Bloom et al. showed that Ser-40 is
required for the release of Nrf2 from its repressor but not for its
nuclear accumulation or increased stability [91]. The identiﬁcation
of nuclear localisation sequences (NLSs) and nuclear export
sequences (NESs) in Nrf2 suggests that in order to facilitate its
translocation, NLS motifs in Nrf2 are identiﬁed by adaptor proteins
such as importins forming a complex with Nrf2 to transport it to
the nuclear membrane through the nuclear pore complex [92].
Protein kinase CK2 is a highly conserved protein with a broad
range of substrates with functions ranging from signal transduc-
tion, gene transcription, replication and survival. The Nrf2
sequence has approximately 13 potential CK2 target phosphory-
lation sites [93] and the transcription activation domains Neh4 and
Neh5 speciﬁcally have been identiﬁed as target regions which can
be phosphorylated by CK2 in vitro [94]. The phosphorylation of
these sites correlates with the translocation of Nrf2 into the
nucleus and this translocation is reduced in the presence of a CK2
inhibitor [94].
The tyrosine kinase Fyn has been shown to phosphorylate
tyrosine-568 in Nrf2, conferring its nuclear export and degrada-
tion. In the presence of the mutant Nrf2Y568A, nuclear accumulation
of Nrf2 was observed, resulting from a loss of phosphorylation at
tyrosine-568 and a loss of the interaction with exportin Crm1 [95].
Furthermore, Jain and Jaswal showed that GSK3b (glycogen
synthase kinase 3b) acts upstream of Fyn activating its phosphor-
ylation and resulting in its nuclear accumulation. Having
accumulated in the nucleus Fyn is perfectly positioned to
phosphorylate Nrf2 and cause its nuclear export, ubiquitination
and subsequent proteasomal degradation [96]. Additionally,
several serine/threonine residues in Nrf2 have been identiﬁed to
be phosphorylated by a panel of MAP kinases. Keum et al. showed
that p38 phosphorylates Nrf2 and promotes its association with
Keap1 thereby preventing its nuclear translocation. Interestingly,
this effect was reversed by sulforaphane and this is a proposed
mechanism of action for sulforaphane-mediated induction of Nrf2
[97]. Recent studies have highlighted the involvement of JNK (c-
jun N-terminal kinase 1/2) and ERK (extracellular signal-regulated
kinase) in the activation of Nrf2. Butylated hydroxyanisole (BHA)
was shown to increase the phosphorylation of both ERK1/2 and
JNK1/2 to activate Nrf2 which was released from Keap1 and
translocated to the nucleus under the control of ERK and JNK
signalling pathways [98]. In addition, PERK kinase has also been
shown to phosphorylate Nrf2, but the exact site of phosphorylation
is yet to be identiﬁed [99].
The majority of known Nrf2 activators also activate a number of
other kinase pathways for example, tBHQ activates the PI3K/Akt
pathway while BHA activates the MAP kinases [37,98]. The
molecular mechanism underlying their roles in the activation of
these kinase pathways remains poorly understood as activation of
speciﬁc pathways is dependent on a number of factors such as the
chemical characteristics of the inducing agent, the cell type used,
and the sequence of the ARE, ultimately adding to the complexity
of the regulation of Nrf2 by the previously described signalling
pathways.
Despite evidence showing the effect of several Nrf2 activators
on a wide variety of signalling pathways, little is known about the
interplay between these pathways and how they may coordinate
to contribute to the regulation of the Nrf2 pathway. The
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provided insight to the activation of Nrf2 by phosphorylation and it
may act as a ‘‘common downstream effector’’ for a number of Nrf2
inducers [88]. GSK3b is an important regulator of several
metabolic processes including glycogen metabolism, Wnt signal-
ling and apoptosis [100]. GSK3b can stabilise Nrf2 by phosphory-
lating the Neh6 region which in turn is proposed to facilitate its
ubiquitination by adaptor protein b-TrCP which forms a complex
with Cullin-1 to form a complete E3 ligase [101]. GSK3b is a
downstream target of multiple kinase cascades i.e. Akt and MAPK,
and the activation of these pathways inhibits GSK3b through
phosphorylation at multiple sites. It is proposed that the Nrf2
activator nordihydroguaiaretic acid (NDGA) targets these kinase
cascades, inhibiting GSK3b, in turn stabilising Nrf2 via its reduced
phosphorylation and ubiquitination [88]. Evidence [100] and
knowledge of GSK3bs relationship with other transcription factors
NF-AT [102] and cyclin-1 [103] supports the latter. GSK3b
inhibition promotes Nrf2 stabilization in Keap1-deﬁcient cells
[88], in Keap1/mice and in the presence of the mutant Nrf2DETGE
whereby Keap1 cannot bind to Nrf2 [101] thereby suggesting that
GSK3b degrades Nrf2 in a Keap1-independent manner. It is
possible that GSK3b phosphorylates these residues with/without
other kinases but this requires further investigation.
Knowing that both ubiquitination and phosphorylation play a
role in the regulation of Nrf2, it comes as no surprise that the
acetylation of Nrf2 also plays a role in the regulation of this pathway.
The transcriptional co-activators p300/CBP acetylate histones to
facilitate chromatin decondensation and recruit RNA polymerase
machinery [104,105], have been shown to associate with Nrf2
[106,107] and other transcription factors such as NF-kB [108]. p300/
CBP binds to Nrf2 in response to oxidative stress induced by arsenite
and acetylates a number of lysine residues within the Neh1 DNA
binding region of Nrf2. Mutations of these lysine sites to arginine
results in no changes in Nrf2 protein stability but does compromise
the ability of Nrf2 to bind to DNA [106]. It is probable that this
mechanism exerts itself downstream of the Nrf2/Keap1 complex
and enhances the ability of Nrf2 to bind to DNA.
The number of factors which have been shown to be involved in
the post translational modiﬁcation of Nrf2 highlights just how
complicated and high regulated this pathway is. The clariﬁcation of
the interplay between each of the pathways involved will help to
further our understanding of cell defence and may highlight
potential therapeutic targets.
3.4. Protein stability and binding partners
A number of Nrf2 activators such as tBHQ and sulforaphane
have been associated with increases in Nrf2 protein stability in
what has been ascribed to an increase in the half-life of Nrf2 rather
than an increase in the rate of protein translation. Whilst most of
the proteins of the BTB-Kelch super-family are yet to be
understood, a few of them have been shown to function in E3
ubiquitination and proteasomal degradation by acting as a
substrate adaptor for the Cul3-based E3 ubiquitin ligase [3].
Following the identiﬁcation of Keap1, a member of this family, to
function as a substrate for Cul3-based E3 ubiquitin ligase, other
BTB-Kelch proteins have been identiﬁed including ectoderm-
neural cortex protein 1 (ENC1) [109]. ENC1 has a similar sequence
and domain organization to Keap1 suggesting that their functions
may be similar. A nuclear matrix protein found in the nervous
system, ECN1 has an important role in neuronal differentiation and
its ectopic expression has been linked to brain tumorigenesis by
augmenting cell proliferation and inhibiting apoptosis [3]. ENC1
can form a complex with Cul3–Rbx1 and facilitate its own
ubiquitination however no ubiquitination of Nrf2 has been seen.
Interestingly, it can reduce the protein levels of Nrf2 as well as thetranscription of Nrf2 dependent genes (NQO1, HO-1) [3]. As ECN1
had no effect on Nrf2 mRNA nor its stability it is proposed that it
down regulates the rate of Nrf2 protein synthesis [3] the
mechanism of which remains to be understood.
Okadaic acid, a protein phosphatase inhibitor, which induces
intracellular hyper-phosphorylation, increases Nrf2 stability
thereby further supporting increased stability as a mechanism
of Nrf2 activation [37]. tBHQ stabilization of Nrf2 is dependent on
the MAPK/ERK signalling cascade as Nrf2 induction by tBHQ is
inhibited in the presence of MAPK/ERK inhibitors suggesting that
the MAPK/ERK signalling cascade drives this stability through
phosphorylation [37]. DJ-1 – a protein associated with Parkinson’s
and cancer belonging to the Thi/PfpI superfamily – stabilizes Nrf2
by impeding its association with Keap1, thus reducing Nrf2
ubiquitination and subsequent degradation [110]. Thus far, no
physical interaction has been seen between DJ-1 and Nrf2, Keap1
or Cullin3 and this interaction seems to be cell type speciﬁc
[110,111]. As for direct binding partners other than Keap1, Nrf2 has
been shown to interact with p21, a cyclin dependent kinase (CDK)
(Fig. 3) which binds with Nrf2 at the DLG and ETGE motifs through
its C-terminal KRR motif to stabilize Nrf2 and thus confer
protection against oxidative stress however the exact mechanism
remains to be elucidated [112].
Recently, caveolin-1 has been identiﬁed as an Nrf2 binding
partner (Fig. 3). Caveolin-1 is a scaffold protein in caveolar
membranes and is involved in signal transduction and the uptake
of lipophilic compounds [113]. Caveolin-1 interacts with a number
of proteins such as; Toll-like receptor 4; LC3B, a constituent of the
autophagy machinery; Fas and survivin to regulate various
biological processes such as cholesterol homeostasis and apoptosis
[113,114]. A study by Zheng et al. highlighted a possible
association between Caveolin-1 and Nrf2 [114] and this was
further conﬁrmed by Li et al. who used siRNA to knock-down
Caveolin-1 which resulted in a dissociation of Nrf2 and Keap1. On
the other hand, ectopic expression of Caveolin-1 did not cause any
changes in the Nrf2/Keap1 association but further reduced the
transcriptional activity of Nrf2. They went on to show that Nrf2
binds Caveolin-1 via a ‘‘caveolin-1 binding motif’’ and mutagenesis
of this motif reduced the association between Caveolin-1 and Nrf2
whist enhancing the association between Keap1 and Nrf2. They
propose that Caveolin-1 may compete with Keap1 for binding to
Nrf2 [113].
3.5. Nrf2 cysteine modiﬁcation
Although much attention has been focused on the modiﬁcation
of reactive cysteine residues in Keap1, the modiﬁcation of
cysteines in Nrf2 is another possible mechanism for its regulation.
Li et al. characterised a nuclear export sequence in the Neh5
transactivation domain which contains a reactive cysteine residue
at position 183. Mutating this residue (C183A) resulted in reduced
translocation rates of Nrf2 compared to wild type following the
activation of Nrf2 by tBHQ and H2O2while no signiﬁcant effect was
seen on Keap1 [115]. Under the conditions of oxidative stress or in
the presence of electrophiles, it is possible that modiﬁcation at Cys-
183 prevents the binding of exportin Crm1 to this Neh domain
resulting in nuclear accumulation Nrf2. As of yet, no mass
spectrometry techniques have been performed to detect the
formation of any sulfydryl adducts on this residue and it should be
noted that there is currently no strong evidence to support the
modiﬁcation of Nrf2 protein itself.
4. Conclusion
In this commentary, we have provided an overview of the
current understanding of Keap1-dependent and -independent
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of Nrf2 in the regulation of multiple biological processes including
the pathogenesis of a number of conditions ranging from cancer,
autoimmune disorders and chronic diseases. Understanding the
molecular mechanisms underlying the regulation of Nrf2 and its
activation by electrophiles and xenobiotics will be key to both the
improvement of current and the development of novel strategies
for the therapeutic manipulation of this pathway. It is safe to say
that there are a multitude of mechanisms playing a role in the
regulation of this pathway however it is not yet possible to say
which may be the most important. What is interesting is that there
are so many alternative pathways for the activation of Nrf2 and
these potentially act as fail safe mechanisms to ensure the
sufﬁcient activation of Nrf2 in times of stress or prevent its
constitutive activation. Under basal intracellular redox conditions,
Keap1 continuously drives the regulation of Nrf2 maintaining low
cellular levels of the protein however under conditions of stress
(chemical/oxidative), the regulation of Nrf2 becomes complex
involving both Keap1-dependent and -independent mechanisms.
In the presence of electrophiles and oxidants, it is proposed that
the modiﬁcation of an array of cysteine residues in Keap1 is
primarily responsible for the obstruction of Nrf2 proteasomal
degradation and thus an increase in its transcriptional activity
however changes in Nrf2s mRNA levels, intracellular localisation,
transcriptional activity, and stability for the most part mediated by
post-translational modiﬁcations also seem to be involved in the
activation of this pathway. These mechanisms of Keap1-indepen-
dent regulation may occur under both redox sensitive and
insensitive conditions and may aid in the ﬁne tuning of the
regulation of Nrf2 levels under basal conditions.
The major limitation on the understanding of the function of
Keap1 modiﬁcations in the activation of Nrf2 is the current
technologies employed to study it. Recent advances in proteomic
technologies (shot gun proteomics, LC–ESI-MS/MS, MRM) have
allowed the detection of direct protein adducts and have facilitated
the detection of a multitude of drug protein targets resulting in the
development of an online database (Target Protein Database) of the
common protein alkylation patterns of a variety of drugs. Whilst
there is much evidence supporting Keap1 modiﬁcation as a
mechanism for regulating Nrf2 in vitro, this is not yet unequivocal,
and certainly this is yet to be proven in vivo [116]. Combining
proteomics with functional protein assays as well as knockout
animals and RNA interference (RNAi), will hopefully lead to an
understanding of the functional relevance of direct protein adduct
formation and protein interactions which will be of particular
interest to those working in the Nrf2/Keap1 ﬁeld. Additionally, the
development of cell lines containing bacterical artiﬁcial chromo-
somes (BACs) expressing the protein of choice with a ﬂuorescent
tag at close to physiological levels will help us understand the
interaction between different members of this pathway.
The publication of the Nrf2 interactome and regulome in 2012
highlights a vast array of potential proteins involved in the
regulation of this pathway including NF-kB [117]. The fact that
there is interplay between these two cell defence pathways
provides evidence for a coordinated response to insult to confer
cell protection, however the exact mechanisms by which they each
may play a role in the regulation of the other pathway remains to
be determined. The activation of the NF-kB pathway has been
associated with the previously mentioned Sequestosome1 (p62).
Sequestosome-1 contains a number of protein binding domains
which allows it to homodimerise and form aggregates or speckles.
Within these speckles, sequestosome-1 associates with and
activates the E3 ligase TRAF6 which has been linked to the
activation of NF-kB [118]. The bone disorder Pagets disease
characterised by increased osteoclastogenic activity resulting in
enlarged and misshapen bones is associated with variousmutations in the Sequestosome-1 gene and the phenotype is
synonymous with mice deﬁcient in TRAF6 [118]. Taken together,
the link between the Nrf2 and NF-kB pathways via both Keap1 and
p62 highlights the importance of the regulation and coordination
of these pathways in human health and disease.
There is a great deal of research being undertaken in order to ﬁll
the knowledge gaps addressed in this commentary and to fully
characterize this pathway in terms of the multiple functions of this
transcription factor, its binding partners and co-factors, the various
signalling cascades which co-ordinate to regulate it and the
downstream effects. Whilst it is evident that Nrf2 is regulated by
both Keap1-dependent and Keap1-indpendent mechanisms, there
are still questions to be answered. What will be very interesting to
uncover is the relative importance of each of these mechanisms in
the activation and regulation of the Nrf2 pathway. For example, of
the numerous kinase pathways discussed in this commentary, are
they all of importance physiologically? Are they under the control
of endogenous factors or only via exogenous Nrf2 modulators?
The role of Nrf2 in a number of pathological states and its links
to cancer is clearly very important, and a full exploration and
understanding of Nrf2 regulation will likely be of value in
designing better therapies in the future. With a better under-
standing of the exact mechanisms of regulation of this pathway, it
may be useful and possible to design therapies that do not target
Nrf2 directly but inﬂuence other members of the pathway and to
ﬁne-tune the activation of the pathway to cater to individual
needs. As Nrf2 has been shown to be up-regulated by both non-
hepatotoxic and hepatotoxic doses of acetaminophen in vivo [119]
and Nrf2/mice are more susceptible to drug induced toxicities, it
is evident that Nrf2 contributes to the cell’s attempt to defend itself
against toxicity and potentially drug induced liver injury (DILI) and
adverse drug reactions (ADRs) which are – for the most part –
responsible for drug attrition [120]. A more complete understand-
ing of this pathway may help us to further our knowledge of these
phenomena and potentially design novel assays to discern drug
safety.
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